Free Newsletter
Are black box warnings inevitable?
A sociologist and health policy researcher has some stern language for drugmakers and their regulators. "Drug disasters are literally built into the current system of drug testing and approvals in the United States," Donald Light said in presenting his figures on new drugs to the American Sociological Association.
According to Light's data review, one in seven new drugs is superior to existing ones, but two in every seven end up emblazoned with a black box, an adverse reaction warning--or they're withdrawn.
And all those post-marketing adverse event reports and black box warnings? They're almost inevitable, given the fact that drugmakers test their products on patients that are typically healthier than the entire population actually targeted by the drugs. And trials are long enough only to pick up short-term side effects, Light said.
Some would argue that the uptick in drug warnings is actually a reflection of the FDA's newly cautionary stance rather than an indication that drug safety is slipping overall. Check out Light's data and see what you think.
- read the post at Pharmalot
Related Articles:
FDA quick to reject drugs as it gets more cautious
Industry exec says FDA approval process too strict
Comments
Post new comment
Paid Research Reports
- The Specialty Pharma Market Outlook: Key players, new company growth models and emerging opportunities
- Investigating Clinical Trial Costs: Comparative analysis of trial cost components in key geographies
- Clinical Trial Recruitment Strategies: Optimizing patient recruitment and retention in late stage clinical trials
- Pipeline Insight: Therapeutic Cancer Vaccines - Prospect of first approval set to reinvigorate interest from major companies
- Stakeholder Opinions: Vaccines in Emerging Markets (Asia) - Opportunities in China, India, South Korea and Taiwan
- Big Pharma Performance Before, During and Beyond the Global Recession






SHARE
WITH: